Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (291-300 of 505) with videos related to

Pageof 51
Sort By:
The European Respiratory Journal|September 8, 2018
Inhaled corticosteroids in COPD: friend or foe?Alvar Agusti, Leonardo M Fabbri, Dave Singh, et al.
Pulmonary Pharmacology & Therapeutics|October 9, 2017
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studiesDean Quinn, Christopher N Barnes, Wayne Yates, et al.
Respiratory Medicine|January 3, 2009
Prevalence of airflow obstruction in patients attending a rapid access chest pain clinicHelen C Francis, Wendy Colecliffe, Michelle L Hazell, et al.
BMC Pulmonary Medicine|November 19, 2014
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyDave Singh, Paul W Jones, Eric D Bateman, et al.
Children (Basel, Switzerland)|September 27, 2025
Expanding Access to Presurgical Cleft Care: Digital Nasoalveolar Molding with Clear Aligners in a Rural Low-Income PopulationDiogo C Frazao, Miguel A C Salgado, Ryan J Cody, et al.
Respiratory Research|September 10, 2020
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilatorDave Singh, Victor Balaguer, Carol Astbury, et al.
American Journal of Respiratory and Critical Care Medicine|June 10, 2026
Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical TrialsGerard J Criner, Henrik Watz, MeiLan K Han, et al.
BMJ Open Respiratory Research|June 17, 2026
Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152aSebastian Moreira, Laura Clow, Emily Coles-Piper, et al.
Journal of Cellular and Molecular Medicine|December 28, 2020
The relationship between airway immunoglobulin activity and eosinophils in COPDThomas Southworth, Andrew Higham, Umme Kolsum, et al.
Clinical and Translational Science|August 21, 2023
Study protocol: A comparison of mobile and clinic-based spirometry for capturing the treatment effect in moderate asthmaElena S Izmailova, Rachel Kilian, Jessie P Bakker, et al.
Pageof 51

Showing results (291-300 of 505) with videos related to

Sort By:
Pageof 51
The European Respiratory Journal|September 8, 2018
Inhaled corticosteroids in COPD: friend or foe?Alvar Agusti, Leonardo M Fabbri, Dave Singh, et al.
Pulmonary Pharmacology & Therapeutics|October 9, 2017
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studiesDean Quinn, Christopher N Barnes, Wayne Yates, et al.
Respiratory Medicine|January 3, 2009
Prevalence of airflow obstruction in patients attending a rapid access chest pain clinicHelen C Francis, Wendy Colecliffe, Michelle L Hazell, et al.
BMC Pulmonary Medicine|November 19, 2014
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyDave Singh, Paul W Jones, Eric D Bateman, et al.
Children (Basel, Switzerland)|September 27, 2025
Expanding Access to Presurgical Cleft Care: Digital Nasoalveolar Molding with Clear Aligners in a Rural Low-Income PopulationDiogo C Frazao, Miguel A C Salgado, Ryan J Cody, et al.
Respiratory Research|September 10, 2020
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilatorDave Singh, Victor Balaguer, Carol Astbury, et al.
American Journal of Respiratory and Critical Care Medicine|June 10, 2026
Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical TrialsGerard J Criner, Henrik Watz, MeiLan K Han, et al.
BMJ Open Respiratory Research|June 17, 2026
Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152aSebastian Moreira, Laura Clow, Emily Coles-Piper, et al.
Journal of Cellular and Molecular Medicine|December 28, 2020
The relationship between airway immunoglobulin activity and eosinophils in COPDThomas Southworth, Andrew Higham, Umme Kolsum, et al.
Clinical and Translational Science|August 21, 2023
Study protocol: A comparison of mobile and clinic-based spirometry for capturing the treatment effect in moderate asthmaElena S Izmailova, Rachel Kilian, Jessie P Bakker, et al.
Pageof 51